Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ZYDUS LIFESCIENCES vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ZYDUS LIFESCIENCES   MYLAN
EQUITY SHARE DATA
    ZYDUS LIFESCIENCES
Mar-23
MYLAN
Dec-18
ZYDUS LIFESCIENCES/
MYLAN
5-Yr Chart
Click to enlarge
High Rs4953,945-   
Low Rs3192,171-   
Sales per share (Unadj.) Rs170.31,815.3-  
Earnings per share (Unadj.) Rs19.849.3-  
Cash flow per share (Unadj.) Rs26.9389.2-  
Dividends per share (Unadj.) Rs6.000-  
Avg Dividend yield %1.50-  
Book value per share (Unadj.) Rs173.01,963.8-  
Shares outstanding (eoy) m1,012.20514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x2.41.7 141.9%   
Avg P/E ratio x20.662.0 33.2%  
P/CF ratio (eoy) x15.17.9 192.5%  
Price / Book Value ratio x2.41.6 151.1%  
Dividend payout %30.30-   
Avg Mkt Cap Rs m412,1441,573,481 26.2%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m24,5640-   
Avg. sales/employee Rs Th026,685.0-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0724.6-  
INCOME DATA
Net Sales Rs m172,374933,975 18.5%  
Other income Rs m4,7460-   
Total revenues Rs m177,120933,975 19.0%   
Gross profit Rs m29,677241,678 12.3%  
Depreciation Rs m7,227174,877 4.1%   
Interest Rs m1,29944,921 2.9%   
Profit before tax Rs m25,89721,880 118.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,878-3,481 -168.9%   
Profit after tax Rs m20,01925,361 78.9%  
Gross profit margin %17.225.9 66.5%  
Effective tax rate %22.7-15.9 -142.7%   
Net profit margin %11.62.7 427.7%  
BALANCE SHEET DATA
Current assets Rs m100,082521,531 19.2%   
Current liabilities Rs m55,267380,253 14.5%   
Net working cap to sales %26.015.1 171.9%  
Current ratio x1.81.4 132.0%  
Inventory Days Days5084 60.2%  
Debtors Days Days9493 100.2%  
Net fixed assets Rs m144,776181,176 79.9%   
Share capital Rs m1,012497 203.5%   
"Free" reserves Rs m174,1460-   
Net worth Rs m175,1581,010,390 17.3%   
Long term debt Rs m01,090,535 0.0%   
Total assets Rs m244,9402,710,259 9.0%  
Interest coverage x20.91.5 1,407.9%   
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x0.70.3 204.2%   
Return on assets %8.72.6 335.6%  
Return on equity %11.42.5 455.3%  
Return on capital %15.53.2 488.3%  
Exports to sales %39.20-   
Imports to sales %11.90-   
Net fx Rs m47,0330-   
CASH FLOW
From Operations Rs m26,888194,080 13.9%  
From Investments Rs m11,712-100,318 -11.7%  
From Financial Activity Rs m-44,004-90,414 48.7%  
Net Cashflow Rs m-5,3381,608 -332.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 82.88 Rs / USD

Compare ZYDUS LIFESCIENCES With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare ZYDUS LIFESCIENCES With: TRIDENT LIFELINE  ISTREET NETWORK  LINCOLN PHAR  SANJIVANI PA  ZENITH HEALTH  



Today's Market

Sensex Today Trades Lower | Metal & PSB Stocks Shine | TCS, Apollo Tyre Drop 3% Sensex Today Trades Lower | Metal & PSB Stocks Shine | TCS, Apollo Tyre Drop 3%(10:30 am)

Asian shares slipped before a Bank of Japan policy decision where authorities are likely to bring an end to the world's last negative rates regime.